Shukra Pharmaceuticals Limited (BOM:524632)
India · Delayed Price · Currency is INR 41.51
+0.08 (0.19%)
At close: Aug 17, 2026
Shukra Pharmaceuticals Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 748.59 | 567.27 | 325.87 | 745.73 | 588.34 | 204.86 |
Other Revenue | - | - | - | - | 6.59 | -0 |
| 748.59 | 567.27 | 325.87 | 745.73 | 594.93 | 204.86 | |
Revenue Growth | 91.91% | 74.08% | -56.30% | 25.35% | 190.41% | 82.97% |
Cost of Revenue | 135.43 | 158.49 | 82.92 | 445.34 | 454.25 | 105.17 |
Gross Profit | 613.15 | 408.78 | 242.95 | 300.39 | 140.68 | 99.69 |
Selling, General & Admin | 96.01 | 70.37 | 72.02 | 81.76 | 53.83 | 55.4 |
Other Operating Expenses | 11.36 | 5.19 | 16.36 | 2.03 | 21.88 | 14.94 |
Operating Expenses | 144.75 | 109.99 | 118.43 | 104.29 | 94.09 | 86.96 |
Operating Income | 468.4 | 298.8 | 124.52 | 196.09 | 46.59 | 12.73 |
Interest Expense | -12.54 | -10.93 | -5.21 | -2.76 | -2.56 | -2.81 |
Interest & Investment Income | - | - | 14.79 | 5.59 | 0.64 | 0.31 |
Other Non Operating Income (Expenses) | - | -0 | -0.74 | -0.09 | -0.25 | -0.05 |
EBT Excluding Unusual Items | 455.86 | 287.87 | 133.37 | 198.83 | 44.42 | 10.18 |
Pretax Income | 455.86 | 287.87 | 133.37 | 198.83 | 44.42 | 10.18 |
Income Tax Expense | 115.98 | 67.28 | 37.61 | 13.46 | 0.35 | 2.67 |
Net Income | 339.87 | 220.58 | 95.75 | 185.37 | 44.07 | 7.51 |
Net Income to Common | 339.87 | 220.58 | 95.75 | 185.37 | 44.07 | 7.51 |
Net Income Growth | 235.86% | 130.37% | -48.35% | 320.68% | 486.98% | 299.10% |
Shares Outstanding (Basic) | 420 | 441 | 438 | 438 | 67 | 63 |
Shares Outstanding (Diluted) | 420 | 441 | 438 | 438 | 67 | 63 |
Shares Change | -7.31% | 0.75% | - | 551.03% | 7.38% | - |
EPS (Basic) | 0.81 | 0.50 | 0.22 | 0.42 | 0.66 | 0.12 |
EPS (Diluted) | 0.81 | 0.50 | 0.22 | 0.42 | 0.66 | 0.12 |
EPS Growth | 262.37% | 128.66% | -48.35% | -35.38% | 446.67% | 299.10% |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | - | -117.99 | 51.75 | -69.57 | -13.22 | 64.39 |
Free Cash Flow Per Share | - | -0.27 | 0.12 | -0.16 | -0.20 | 1.03 |
Dividend Per Share | - | 0.010 | 0.010 | 0.100 | 0.013 | 0.013 |
Dividend Growth | - | 0% | -90.00% | 700.00% | 0% | - |
Gross Margin | 81.91% | 72.06% | 74.55% | 40.28% | 23.65% | 48.66% |
Operating Margin | 62.57% | 52.67% | 38.21% | 26.30% | 7.83% | 6.21% |
Profit Margin | 45.40% | 38.88% | 29.38% | 24.86% | 7.41% | 3.66% |
Free Cash Flow Margin | - | -20.80% | 15.88% | -9.33% | -2.22% | 31.43% |
EBITDA | 503.92 | 333.23 | 154.57 | 216.59 | 64.96 | 29.35 |
EBITDA Margin | 67.32% | 58.74% | 47.43% | 29.04% | 10.92% | 14.33% |
D&A For EBITDA | 35.52 | 34.43 | 30.05 | 20.5 | 18.38 | 16.62 |
EBIT | 468.4 | 298.8 | 124.52 | 196.09 | 46.59 | 12.73 |
EBIT Margin | 62.57% | 52.67% | 38.21% | 26.30% | 7.83% | 6.21% |
Effective Tax Rate | 25.44% | 23.37% | 28.20% | 6.77% | 0.79% | 26.26% |
Revenue as Reported | 788.73 | 613.12 | 367.94 | 773.88 | 600.3 | 205.67 |
Advertising Expenses | - | - | 3.63 | 21.21 | 0.1 | 0.09 |